A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Recruiting now · Phase 1
Conditions studied: Advanced Malignancies
In brief
This drug-drug interaction (DDI) study aims to evaluate the impact of pelabresib at steady-state plasma concentrations on the pharmacokinetic (PK) profile of A) a single dose of repaglinide and a single dose of midazolam, and B) a single dose of combined drospirenone and ethinyl estradiol. The study will be conducted in adult participants with advanced malignancies for whom no standard or curative treatment options are available.
Key facts
- Study ID
- NCT07340190
- Run by
- Novartis Pharmaceuticals
- People needed
- 24
- Starts
- 2026-06-12
- Expected to finish
- 2028-04-07
- Last updated by the study team
- 2026-07-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Candiolo, TO, Italy (enrolling)
- Novartis Investigative Site — Pozuelo de Alarcón, Madrid, Spain (enrolling)
- Novartis Investigative Site — Barcelona, Spain (enrolling)
- Novartis Investigative Site — Madrid, Spain (enrolling)
- Novartis Investigative Site — Madrid, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.